15 Jul GSK Now Offers Priorix MMR Vaccine
Effective July 15, 2022, PRIORIX (Measles, Mumps, and Rubella Virus Vaccine, Live), will be available for PAA members to preorder. Product availability is anticipated in August.
GSK announced in June that the US Food and Drug Administration (FDA) approved Priorix (Measles, Mumps and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older. Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients.
Log in to view PAA member preferred pricing and rebate opportunity. If you are not a member, Join now.